|
Wednesday 31st March 2021 |
Text too small? |
Cancer diagnostics company, Pacific Edge Limited has concluded a commercial agreement with Facey Medical Group, a physician owned medical group in California. The agreement covers the use of Cxbladder Detect and Cxbladder Monitor for Facey Medical Group patients.
Facey Medical Group is a multi-specialty medical group with over 180 physicians providing care to more than 170,000 patients in the North & East regions of Los Angeles & Ventura Counties in California. This makes it similar in size to the Mid-Central District Health Board in New Zealand. Facey Medical Group is also one of six California physician groups affiliated with, or owned by Providence Health & Services, one of the largest health systems in the Western United States.
CEO of Pacific Edge, David Darling, said: “Physician owned organisations such as the Facey Medical Group are an important customer group for Pacific Edge as we continue to expand the adoption and commercial use of Cxbladder in the US. We were approached by the Group following a number of the urologists utilising our products and we are pleased to move into a formal commercial relationship with them. Whilst test volumes are not expected to be large compared to healthcare organisations such as Kaiser Permanente, this agreement demonstrates the ongoing commercial adoption of Cxbladder in the US as we continue to position Cxbladder as the preferred diagnostic test for urologists evaluating patients for bladder cancer.”
Please see the link below for details:
PEB Concludes Commercial Agreement with Facey Medical Group in US
No comments yet
RUA - Commencement of direct distribution from Tairawhiti
BRW - Floorscape offer not progressed
September 7th Morning Report
CVT - Comvita Limited director nominations
September 4th Morning Report
BRW - Revised offer from Floorscape Limited for 100% of Bremworth
WIN - Winton Appoints Michael Stiassny as Independent Chair
WCO - Offer of new shares to selected investors
GNE - Genesis secures additional gas to strengthen fuel portfolio
FSF - Fonterra provides update on forecast FY26 earnings